Chemotherapy is one of the main treatment approaches for lung cancer. However, few drugs can be used in the post-first-line treatment of lung cancer. Apatinib is a small molecule inhibitor of vascular endothelial growth factor receptor-2 (VEGFR-2) and is widely used in advanced gastric cancer. This study aimed to investigate the therapeutic effect of apatinib in the second-line treatment of lung cancer and explore its underlying mechanism from the aspect of macrophage-mediated epithelial-mesenchymal transition (EMT). The results showed that apatinib attenuated macrophage-induced EMT and migration of lung cancer cells but not normal lung cells, as demonstrated by the loss of epithelial properties and gain of mesenchymal characteristics. Moreover, apatinib selectively decreased hepatocyte growth factor (HGF) secretion in polarized macrophages. Furthermore, apatinib down-regulated the expression of the HGFMet signaling pathway in polarized macrophage-stimulated lung cancer cells. Taken together, our study has identified a novel pathway through which apatinib exerts its anti-cancer functions, and provided a molecular basis for apatinib potential applications in the post-first line treatment of lung cancer.
Introduction
Lung cancer is the most frequently diagnosed malignant tumor and the leading cause of cancer death worldwide.
1,2 Histologically, lung cancer can be divided into small-cell lung cancer and non-small-cell lung cancer (NSCLC), and the latter accounts for more than 70% of lung cancer. 3, 4 In NSCLC, tumor-associated macrophages located in lung carcinomas increase tumor recurrence aer surgery and reduce patient survival. 5, 6 Thus, interference with macrophage polarization may shi macrophage function from a tumor facilitator to a tumor suppressor, suggesting a potential mechanism for lung cancer therapy.
To date, EGFR tyrosine kinase inhibitors (EGFR-TKIs) and ALK inhibitors such as getinib and afatinib have been suggested as the rst-line treatment for NSCLC patients with epidermal growth factor receptor (EGFR) mutation and anaplastic lymphoma kinase (ALK) rearrangements. [7] [8] [9] In the NSCLC patients without genetic driver mutation, platinumbased chemotherapy is the best option for rst-line treatment.
Tumor angiogenesis is an essential step for tumor proliferation and metastasis. Vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling pathway has been proved to play crucial role in tumor angiogenesis. 10, 11 Thus, VEGF/VEGFR was considered as a target in cancer therapy. In fact, multiple drugs which target VEGF/VEGFR have received the Food and Drug Administration approval and have shown encouraging efficacy in several solid tumors. For example, it was reported that bevacizumab or ramucirumab combined with chemotherapy signicantly improved the progression-free survival (PFS) and overall survival (OS) in NSCLC. 12, 13 However, these anti-angiogenesis drugs were suggested adding to platinum-based doublet chemotherapy as rst-line treatment for advanced NSCLC without driver mutation, and there was little evidence for their application in post-rst-line monotherapy of advanced lung cancer.
Apatinib is an oral small molecule inhibitor of VEGFR-2, and displays efficiency and safety in breast and gastric cancer therapy.
14-16 However, its application on other malignant tumors, such as lung carcinoma is just getting started. Recent studies have reported that high dose (500-825 mg d À1 ) and low dose (250-500 mg d À1 ) of apatinib showed an efficiency and safety in lung cancer patients. [17] [18] [19] In the present study, we used apatinib as a post-rst-line therapy to investigate the underlying mechanism in the aspect of macrophage-mediated EMT. We found that apatinib inhibits macrophage inltration in vivo and suppresses macrophage-induced EMT in vivo and in vitro. Further studies suggested that apatinib inhibits macrophagemediated EMT through HGF-Met signaling pathway.
(PeproTech, Suzhou, China); antibodies to CD68, ZO-1, Ncadherin, vimentin, Slug and b-actin (Santa Cruz Biotechnology, USA); antibodies to bronectin, E-cadherin, Snail, pMet, Met (Abcam, Cambridge, MA). HRP-conjugated secondary antibodies (Vazyme, Nanjing, China). ELISA kit for HGF, EGF, TGF-b1 and IL-6 (R&D Systems, Minneapolis, MN).
Cell culture
A549, H1975 and normal human lung cell line BEAS-2B (ATCC, Manassas, USA) were grown in DMEM complemented with 10% FBS (Life Technologies, Grand Island, USA), 100 IU ml À1 penicillin (Sigma, USA), and 100 mg ml À1 streptomycin (Sigma, USA).
All cells were cultured at 37 C in a 5% CO2 incubator. Human monocyte cell line THP1 was stimulated with phorbol myristate acetate (PMA, 0.1 mM, Thermo Scientic, USA) for 3 hours to generate polarized macrophages. Apatinib or DMSO was added to polarized macrophages for 24 hours, followed by a medium exchange and stimulate with LPS for 24 hours. The supernatant was collected and centrifugated for further studies.
Immunohistochemistry
Paraffin-embedded tissue sections were cut to a thickness of 4 mm. Aer dewaxing, rehydration and blocking, the sections were incubated with CD68 and bronectin antibody overnight at 4 C, followed by incubation with uorophore-conjugated secondary antibody for 1 h. Sections were visualized with a uorescent microscope and quantied by ImageJ soware as before. were adjusted to GAPDH.
Western blot
Total protein samples from cells were prepared by using RIPA buffer. Equal amounts of protein sample were separated by 10% SDS-PAGE and transferred to PVDF membranes (Millipore, Billerica, USA). Membranes were blocked with 5% non-fat milk, and then incubated with primary antibodies and corresponding secondary antibodies. The targeted bands in the membranes were visualized using enhanced chemical luminescence (ECL) and quanticated by ImageJ soware.
Wound healing assay
Conuent cell monolayer were cultured in a 24-well chamber and stroked with a plastic pipette tip. Cells were washed to remove detached and damaged cells. Aer treated with the supernatant of polarized macrophages (which have treated with apatinib or DMSO) for 24 h, the cell migrations were monitored microscopically and the migration distance was measured from 5 points per 1 wound area by the ImageJ soware.
Transwell invasion assay
Cell invasive capacity was detected using a 24-well plate with transwell chamber (0.4 mm pore size, Corning) inserts precoated with Matrigel. Briey, cells (1 Â 10 5 ) were seeded into the upper chamber in serum-free medium. Then, complete medium (containing 10% FBS) was added into the lower chamber. Aer 24 h of indicated treatment, cells in the upper surface of the membranes were removed with cotton swab. The cells that had migrated to the outer side of the membranes were stained with hematoxylin. The stained cells were photographed and counted in 10 random elds. 
Enzyme linked immunosorbent assay (ELISA)
The expression of HGF, epidermal growth factor (EGF), Transforming growth factor (TGF)-b and interleukin (IL)-6 were quantied by ELISA according to the manufacturer's instructions (Sigma, St. Louis, USA). Polarized macrophages induced by different concentrations of apatinib were precoated onto ELISA plates and served as the antigen. o-Dianisidine was used as substrate and the absorbance of the colored horseradish peroxidase (HRP) product was measured spectrophotometrically at 490 nm by an automated microplate reader (Thermo, Waltham, USA).
Statistical analysis
Data were analyzed by SPSS 19.0 soware and the results were expressed as mean AE standard deviation (SD). The statistical signicance of the studies was analyzed using one way ANOVA. The difference was considered signicant at P < 0.05.
Results

Apatinib suppresses polarized macrophage-induced EMT in lung cancer cells
To investigate the effect of apatinib on macrophages, human monocyte cell line THP1 was treated with PMA to generate polarized macrophage. Then, human lung cancer cell line A549 and H1975 and normal human lung cell line BEAS-2B were cultured with the supernatant from polarized macrophages for 24 h. The expressions of EMT-related genes were detected by qPCR and western blot. As shown in Fig. 1A -D, the supernatant from polarized macrophages signicantly increased the mRNA expression of N-cadherin, vimentin and Slug and decreased the level of E-cadherin in A549 and H1975 cells. However, apatinib treated macrophage supernatant effectively corrected these abnormalities. Consistent with the mRNA changes, the supernatant from polarized macrophages signicantly decreased the protein expression of epithelial markers (ZO-1 and E-cadherin) and increased the protein levels of N-cadherin, vimentin, Slug and Snail in A549 and H1975 cells. These changes were reversed when polarized macrophages were pretreated with apatinib ( Fig. 1E-K) . Similarly, no obvious changes were observed in BEAS-2B cells. These results indicate that apatinib suppresses polarized macrophage-induced EMT only in lung cancer cells.
Apatinib inhibits polarized macrophage-induced migration and invasion of lung cancer cells
To determine whether the effect of apatinib on polarized macrophages leads to an inhibition of cellular migration, wound healing assay and transwell invasion assay were carried out. As shown in Fig. 2A and B, polarized macrophages promoted the migration of A549 and H1975 cells. However, apatinib pretreatment signicantly decreased the migration distance in polarized macrophage-stimulated A549 and H1975 cells. In addition, transwell assay showed that polarized macrophages stimulation promoted the invasion of A549 and H1975 cells, which was blocked by apatinib treatment (Fig. 2C  and D) . In addition, the increased percentage of broblast-like cells in MF were strongly decreased under apatinib treatment ( Fig. 2E and F) . These data suggest that apatinib inhibits macrophage-induced migration in lung cancer cells.
Apatinib inhibits the expression of HGF in polarized macrophages
To investigate whether cytokine secretion of polarized macrophages contributes to the EMT progression, the expression of EMT-related cytokines in polarized macrophages was analyzed by qPCR and ELISA. The results showed that apatinib notably decreased the level of HGF in polarized macrophages. However, other EMT-related cytokines, such as EGF, TGF-b1 and IL-6 had no obvious changes in polarized macrophages with or without apatinib stimulation (Fig. 3) . Thus, apatinib inhibits macrophagemediated EMT probably through regulating HGF secretion. 
Apatinib inhibits HGF-induced migration and invasion of lung cancer cells
Based on the above observations, the migration and invasion capacities of lung cancer cells were examined aer HGF stimulation. As shown in Fig. 4 , HGF signicantly increased the migration distance and invasion capacity and the percentage of broblast-like cells of A549 and H1975 cells. As expected, apatinib treatment effectively corrected these abnormalities. These results further indicate that HGF is involved in the macrophagemediated EMT.
Apatinib down-regulates HGF-Met signaling in polarized macrophage supernatant-treated lung cancer cells
We next investigated the expression of the downstream receptors of HGF, EGF, TGF-b1 and IL-6 in polarized macrophage supernatant-treated lung cancer cells. As expected, apatinib dosedependently inhibited the expression of Met in polarized macrophage-stimulated A549 and H1975 cells but not in BEAS-2B cells (Fig. 5A) . However, the expression of EGFR, TGFbR and IL6R was not changed in lung cancer cells or normal lung cells (Fig. 5B-D) . Since HGF-Met signaling mainly depends on Met phosphorylation, we next examined the expression of phosphorylated Met. The results showed that apatinib effectively decreased polarized macrophage-induced phosphorylation of Met in A549 and H1975 cells (Fig. 5E and F) . Taken together, these results suggest that apatinib blocks polarized macrophageactivated HGF-Met signaling in lung cancer cells.
Discussion
To date, platinum-based chemotherapy is the preferred treatment of advanced lung cancer without genetic driver. However, the efficiency of rst-line chemotherapy has reached a threshold and there are fewer options for post-rst-line therapy. Recent studies have reported that combination of antiangiogenic drugs and chemotherapy could signicantly improve PFS and overall OS in advanced NSCLC. 12, 13 It was reported that apatinib inhibits the invasion and migration of lung cancer cells in vitro via RET/Src signaling pathway. 20 Some clinical cases reports demonstrated that apatinib prolonged the PFS in NSCLC patients. 16, 17 In this study, we found that apatinib treatment signicantly attenuated macrophage inltration and EMT of lung tissue. EMT is a developmental cellular process by which polarized epithelial cells lose epithelial properties and cell-cell adhesions, and gain mesenchymal characteristics, 21, 22 which allows the cancer cell to become more invasive, metastatic and form a secondary metastasis.
23 E-cadherin and ZO-1 are required for the formation of stable adherens junction. During EMT, epithelial cells lose E-cadherin and convert into spindle shaped mesenchymal cells by acquiring N-cadherin.
24,25
It was reported that E/N-cadherin switch play a crucial role in cancer progression. Slug and Snail are key regulators of Ecadherin and it was demonstrated that all these factors promotes tumor growth, recurrence and metastasis.
26,27
Vimentin and bronectin are mesenchymal markers and are overexpressed in cancer cells. [28] [29] [30] In the present study, we found that apatinib signicantly reversed macrophage-induced increase of N-cadherin, vimentin, Slug and Snail and decrease of ZO-1 and E-cadherin. Furthermore, apatinib also attenuated EMT-mediated migration and invasion of lung cancer cells.
Previous studies have reported that macrophage derived cytokines stimulate the progression of EMT. 31 Thus, the expression of EMT-related cytokines was examined in polarized macrophages. Among these cytokines, TGF-b1 is considered to be the most common activator of EMT. 32 It promotes EMT through various pathways, such as smad2/3 and Wnt/b-catenin. 33, 34 However, the expression of TGF-b1 is not changed in polarized macrophages aer apatinib stimulation. TGF-b1 interacts with other cytokines to regulate the progression of EMT, such as IL-6 and EGF, and EGF also directly induces EMT. 35, 36 Similarly, the expression of EGF and IL-6 was not signicantly altered by apatinib stimulation. Only the production of HGF was consistent with EMT progression. These data indicated that apatinib attenuated macrophage-induced EMT through inhibiting HGF expression.
HGF is a multifunctional growth factor originally isolated from rat platelets.
37 HGF-Met activation is considered to promote tumor cell proliferation and survival and EMT.
38 HGF and Met are also localized at sites of pathological angiogenesis and are a potent endothelial mitogens. 39 Many studies have reported that inhibition of HGF-Met pathway could attenuate the progression of EGFR-TKI-resistant lung cancer. 40, 41 Overexpression of Met activates ERBB3/PI3K/AKT signaling in EGFR mutant lung cancers, which lead to EGFR-TKI-resistance. In the present study, the results showed that apatinib not only inhibited HGF secretion in polarized macrophages, but also suppressed Met activation in polarized macrophage-stimulated lung cancer cells, suggesting that apatinib attenuated macrophage-induced EMT through HGF-Met signaling pathway. This study reported that apatinib may act as a potential VEGFR inhibitor in suppressing cancer progression. We are now applying a commonly used inhibitor of MET and VEGFRs, Foretinib (GSK1363089), as a positive control of apatinib in lung cancer cells A549 and H1975, in order to convince the effect of apatinib on HGF expressions and EMT in lung cancer. In this study we rst reported that apatinib inhibits macrophage-mediated EMT in lung cancers. Our study not only provided a new insight into apatinib's application in post-rst-line therapy of lung cancer, but also elaborated a novel mechanism of apatinib's tumor-suppressive effect in treatment of lung cancer.
Conclusions
In this study we rst reported that apatinib inhibits macrophage-mediated EMT in lung cancers. Our study not only provided a new insight into apatinib's application in post-rst-line therapy of lung cancer, but also elaborated a novel mechanism of apatinib's tumor-suppressive effect in treatment of lung cancer.
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